[go: up one dir, main page]

PE20191529A1 - Peptidos y metodos para el tratamiento de diabetes - Google Patents

Peptidos y metodos para el tratamiento de diabetes

Info

Publication number
PE20191529A1
PE20191529A1 PE2019001772A PE2019001772A PE20191529A1 PE 20191529 A1 PE20191529 A1 PE 20191529A1 PE 2019001772 A PE2019001772 A PE 2019001772A PE 2019001772 A PE2019001772 A PE 2019001772A PE 20191529 A1 PE20191529 A1 PE 20191529A1
Authority
PE
Peru
Prior art keywords
diabetes
treatment
peptides
methods
cst
Prior art date
Application number
PE2019001772A
Other languages
English (en)
Inventor
Elst Luc Vander
Vincent Carlier
Jean-Marie Saint-Remy
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of PE20191529A1 publication Critical patent/PE20191529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)

Abstract

Referido a un peptido inmunogenico aislado con una longitud de entre 12 y 50 aminoacidos, caracterizado porque comprende la secuencia Cxx[CST]SLQPLALEGSLQK [SEQ ID NO:4] O [CST]xxCSLQPLALEGSLQK [SEQ ID NO:5]. Tambien se refiere a un metodo in vitro para la generacion de una poblacion de celulas T CD4+ citoliticas contra APC que presenta epitopes de insulina. Este peptido se puede usar en el tratamiento o prevencion de diabetes tipo 1.
PE2019001772A 2017-03-09 2018-03-06 Peptidos y metodos para el tratamiento de diabetes PE20191529A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160085 2017-03-09
PCT/EP2018/055501 WO2018162498A1 (en) 2017-03-09 2018-03-06 Peptides and methods for the treatment of diabetes

Publications (1)

Publication Number Publication Date
PE20191529A1 true PE20191529A1 (es) 2019-10-23

Family

ID=58266442

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001772A PE20191529A1 (es) 2017-03-09 2018-03-06 Peptidos y metodos para el tratamiento de diabetes

Country Status (21)

Country Link
US (4) US10808016B2 (es)
EP (1) EP3592765A1 (es)
JP (2) JP7102430B2 (es)
KR (1) KR20190126798A (es)
CN (1) CN110536898B (es)
AU (2) AU2018229741B2 (es)
BR (1) BR112019018616A2 (es)
CA (1) CA3051518A1 (es)
CO (1) CO2019009080A2 (es)
CU (1) CU24596B1 (es)
IL (1) IL268874B2 (es)
MX (1) MX2019010558A (es)
MY (1) MY192295A (es)
NZ (1) NZ755744A (es)
PE (1) PE20191529A1 (es)
PH (1) PH12019502036A1 (es)
RU (1) RU2761653C2 (es)
SA (1) SA519410007B1 (es)
SG (1) SG11201908275XA (es)
WO (1) WO2018162498A1 (es)
ZA (1) ZA201905851B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
WO2009101206A2 (en) * 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
JP7102430B2 (ja) 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
US20230136112A1 (en) * 2019-11-27 2023-05-04 Imcyse Sa Methods for stratifying diabetes patients
WO2021224403A1 (en) * 2020-05-06 2021-11-11 Imcyse Sa Immunogenic peptides with new oxidoreductase motifs
JP2023525276A (ja) 2020-05-06 2023-06-15 アンシス・エスア 延長された酸化還元酵素モチーフを有する免疫原性ペプチド
CA3182369A1 (en) * 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
BR112023024546A2 (pt) 2021-06-01 2024-02-15 Imcyse Sa Métodos de tratamento usando peptídeos imunogênicos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078843B2 (en) * 2005-09-22 2015-07-14 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
AU2009214041A1 (en) * 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
CA2715611C (en) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
WO2009101204A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
US9248171B2 (en) 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
US8999346B2 (en) 2008-02-14 2015-04-07 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
WO2009101206A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
CN103002909B (zh) 2010-03-29 2016-06-29 国家科学研究中心 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) * 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
JP7102430B2 (ja) * 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
TWM593454U (zh) 2019-11-11 2020-04-11 競泰股份有限公司 多鑰匙鎖心

Also Published As

Publication number Publication date
CA3051518A1 (en) 2018-09-13
BR112019018616A2 (pt) 2020-04-28
JP2020509067A (ja) 2020-03-26
CN110536898B (zh) 2023-09-08
CN110536898A (zh) 2019-12-03
AU2018229741B2 (en) 2021-09-02
JP7102430B2 (ja) 2022-07-19
IL268874B2 (en) 2023-09-01
MY192295A (en) 2022-08-17
IL268874B1 (en) 2023-05-01
US10808016B2 (en) 2020-10-20
RU2761653C2 (ru) 2021-12-13
US20190352348A1 (en) 2019-11-21
RU2019126232A3 (es) 2021-06-01
US11407795B2 (en) 2022-08-09
MX2019010558A (es) 2019-10-21
EP3592765A1 (en) 2020-01-15
PH12019502036A1 (en) 2020-06-15
AU2021277735A1 (en) 2021-12-23
IL268874A (en) 2019-10-31
US20240092843A1 (en) 2024-03-21
RU2019126232A (ru) 2021-04-10
CO2019009080A2 (es) 2019-08-30
US20200407406A1 (en) 2020-12-31
US20220411476A1 (en) 2022-12-29
US11760782B2 (en) 2023-09-19
SA519410007B1 (ar) 2023-02-16
SG11201908275XA (en) 2019-10-30
KR20190126798A (ko) 2019-11-12
AU2018229741A1 (en) 2019-08-15
WO2018162498A1 (en) 2018-09-13
NZ755744A (en) 2023-07-28
ZA201905851B (en) 2021-04-28
JP2022125216A (ja) 2022-08-26
CU20190078A7 (es) 2020-04-02
CU24596B1 (es) 2022-05-11

Similar Documents

Publication Publication Date Title
PE20191529A1 (es) Peptidos y metodos para el tratamiento de diabetes
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
PE20180253A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer
PE20180487A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cancer
PE20170940A1 (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
PE20181897A1 (es) Inmunoterapia contra el melanoma y otros tipos de cancer
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
AR069362A1 (es) Variantes de enzimas asparraginasas y sus usos
PE20180505A1 (es) Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres
MX2018005063A (es) Polipéptidos condicionalmente activos.
PE20230321A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
AR105766A1 (es) Polipéptidos que tienen actividad de pululanasa adecuados para usar en licuefacción
MX2016002937A (es) Vacuna oncologica.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
PE20191711A1 (es) Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer
CL2018002493A1 (es) Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227)
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.